Volume 13, Issue Supplement_1, February 2024
Advances in Pediatric Transplant Infectious Diseases
SUPPLEMENT ARTICLES
Current Landscape and Future Directions of Pediatric Transplant Infectious Diseases
Pre-Transplantation Strategies for Infectious Disease Mitigation and Prevention
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients
Cytomegalovirus continues to cause significant morbidity and mortality in pediatric hematopoietic cell and solid organ transplant recipients. With few antivirals available, their associated toxicities, and emerging resistance, newer medications are of pivotal importance.
Cytomegalovirus Cell-mediated Immunity Assays in Pediatric Transplantation
In this article, we review the immune response to CMV infection to highlight the rationale for CMI assays; describe available commercial assays and strategies for their use; and summarize relevant literature regarding the use of CMI assays in transplant recipients.
A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines
Impact of Respiratory Viral Infections in Transplant Recipients
Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation
Nontuberculous Mycobacterial Infections in Pediatric Solid Organ Transplant and Hematopoietic Cell Transplant Recipients
Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective
Several antifungal agents have received or may soon receive approval for clinical use. These agents provide novel mechanisms of action or formulations that should expand the therapeutic options for invasive fungal disease. Pediatric-specific data for these agents remain limited.
The Microbiome and Pediatric Transplantation
Transplantation has substantial effects on the microbiomes of children, with implications for survival and the risks of infection, graft-versus-host disease, and graft rejection. Studying relationships between the microbiome and these outcomes can offer insights into underlying mechanisms and potential interventions.
